| http://www.cninfo.com.cn/new/disclosure/detail?stockCode=002636&announcementId=122411 | 002636 | 金安国纪 | 9942&orgId=9900021766&announcementTime=2025 | -07-10 | | | --- | --- | --- | --- | --- | --- | | http://www.cninfo.com.cn/new/disclosure/detail?stockCode=000691&announcementId=122421 | 000691 | *ST亚太 | 5359&orgId=gssz0000691&announcementTime=2025 | -07-21 | | | http://www.cninfo.com.cn/new/disclosure/detail?stockCode=000607&announcementId=122418 | 000607 | 华媒控股 | 8769&orgId=gssz0000607&announcementTime= ...

浙江维康药业股份有限公司 关于股票交易异常波动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股票交易异常波动的具体情况 证券代码：300878 证券简称：维康药业 公告编号：2025-029 浙江维康药业股份有限公司（以下简称"公司"）股票连续三个交易日内 （2025年7月17日、2025年7月18日、2025年7月21日）收盘价格涨幅偏离值累计超 过30%，根据深圳证券交易所创业板的相关规定，属于股票交易异常波动的情况。 二、公司关注并核实相关情况 针对公司股票异常波动情况，公司董事会对公司、控股股东及实际控制人就相 关事项进行了认真核实，现对有关情况说明如下： 1、截至本公告日，公司前期披露的信息不存在需要更正、补充之处； 公司董事会确认，截至本公告披露之日，公司没有任何根据《深圳证券交易所 创业板股票上市规则》等有关规定应予以披露而未披露的事项或与该事项有关的筹 划、商谈、意向、协议等；董事会也未获悉本公司有根据《深圳证券交易所创业板 股票上市规则》等有关规定应予以披露而未披露的、对本公司股票及其衍生品种交 易价格产生较大影响的信息。公司前 ...

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 7月17日，高股息资产延续回调走势，市场的天平再次倾向了创新药、算力、军工等赛道，赚钱效应出 现明显好转。 截至收盘，上证指数涨0.37%，报3516.83点；深证成指涨1.43%，报10873.62点；创业板指涨1.75%，报 2269.33点。 值得一提的是，在A股市场走高之际，外资看多的声音逐渐增多。景顺全球主权资产管理研究最新发布 显示，国际投资机构对中国市场的兴趣明显回升。韩国证券存托结算院（KSD）最新数据也显示，截至 7月15日，今年以来韩国投资者对中国内地与香港股市的累计交易额已超过54亿美元，中国市场成为韩 国股民的第二大海外投资目的地，仅次于美国市场。 赛道股全线爆发 创新药概念延续强势，维康药业（维权）、迈威生物实现20%涨停，首药控股、神州细胞、复旦张江等 多股上涨超10%。 | 股份 | 大事 | 资讯 | 公告 | 研究报告 | 贡献点数 | | | --- | --- | --- | --- | --- | --- | --- | | 代码 | | 名称 | * ● | 最新 | 张唱歌下 | 金额 | | ...

从消息面来看，近期，创新药板块的利好消息不断。接下来，这个板块的行情是否会持续下去呢？ 创新药概念股集体爆发 自6月底以来，创新药板块一路上行，最近几天更是加速上涨。7月17日，创新药板块指数涨幅超过3%，成都 先导、迈威生物、维康药业、塞力医疗、力生制药、亚太药业、信立泰等近20只相关概念股涨停或涨超10%。 7月17日，创新药领域又传来一则好消息。据北京日报报道，近日，我国自主研发的、抗呼吸道合胞病毒的创 新药——齐瑞索韦列入世界卫生组织儿童药物优化优先清单，有望为全球儿童带来可及、可负担的有效治疗。 据报道，世界卫生组织儿童药物优化（PADO）项目通过凝聚监管机构、资助方与制造商共识，推动有紧迫需 求的儿童药物加速开发，工作内容包括确定研发的重点优先产品及其理想的产品特性。 创新药板块，再次掀起涨停潮！ 今日（7月17日），A股三大指数集体拉升，截至收盘，沪指涨0.37%，深证成指涨1.43%，创业板指涨1.76%。 盘面上，创新药、CPO、AI硬件等方向领涨。其中，创新药概念股集体大涨，成都先导、塞力医疗、力生制药 等近20只相关概念股涨停或涨超10%。 在港股市场上，创新药概念股也集体爆发，截至收盘 ...

Group 1: Stock Performance - Zhejiang Zhenyuan and Asia-Pacific Pharmaceutical both achieved a 2-day limit-up with increases of 10.01% and 9.98% respectively, driven by innovation in pharmaceuticals [2] - Chengdu XianDao saw a first board listing with a significant rise of 20.02%, attributed to innovative drug developments [2] - TaiJing Technology and YanHua Intelligent both recorded first board listings with increases of 9.97% and 9.94%, linked to Huawei's influence in robotics [5] Group 2: AI and Robotics - Nvidia's CEO suggested that Huawei's AI chips could potentially replace Nvidia's offerings, indicating a competitive shift in the AI chip market [4] - The domestic robotics industry is gaining traction with significant orders being awarded, highlighting its importance in national competition [7] Group 3: Market Trends - The light communication sector is expected to see sustained growth due to high demand in both domestic and international markets, with performance likely to continue improving [13] - The low-altitude economy is gaining attention, with a notable $1 billion procurement agreement signed for eVTOL aircraft, indicating growth potential in this sector [17] Group 4: Consumer and Retail - The Chinese government is implementing measures to boost consumer spending, which is expected to positively impact the retail sector [21] - Companies like Guoguang Chain and Hanshang Group have seen first board listings with increases of 9.98% and 9.97%, reflecting the positive sentiment in the retail market [23] Group 5: Solar and Food & Beverage - The price of polysilicon has increased by 12.4% week-on-week, indicating a rising trend in the solar industry [24] - The food and beverage sector is also benefiting from government initiatives aimed at enhancing consumer demand, with companies like Huangshi Group seeing a 10.10% increase [26]

近期， 创新药 概念股 维康药业 （SZ300878）以20CM涨停引发了市场的广泛关注。作为一家专注于现 代 中药 及西药研发、生产和销售的企业，维康药业的资金流向并非孤立事件，而是整个创新药板块集 体走强的缩影。从市场情绪到资金流向，从政策利好到公司基本面变化，多重因素共同推动了这一现象 的发生。本文将深入剖析维康药业涨停的原因，并结合行业趋势和公司自身的动态，探讨其背后的投资 逻辑。 事件背景与核心内容 创新药板块在2025年7月17日早盘表现异常强劲，维康药业更是在开盘后迅速封板，涨幅达到19.99%， 触发20CM涨停限制。与此同时， 成都先导 、 力生制药 等个股也纷纷跟涨，板块整体情绪高涨。值得 注意的是，这一轮上涨并非偶然，而是多重因素叠加的结果。 首先，国家医保局于7月15日宣布启动第十一批国家组织药品集中采购工作，这为创新药企业带来了政 策层面的利好预期。其次，维康药业自身的基本面也出现了积极信号——公司近日公告其 维生素 K1滴 剂药品注册上市许可申请已获受理。尽管公司在过去一年因信披违规等问题被罚款超千万元，但此次产 品管线的进展无疑为其注入了新的活力。 此外，市场情绪的升温也为维康药 ...

Market Overview - The A-share market opened slightly lower on July 17 but then experienced a rebound, with all three major indices showing positive performance, particularly the ChiNext index which rose nearly 1% [2] - The total market capitalization reached 14.20 trillion CNY, with a trading volume of 7698.06 million hands and a turnover rate of 1.46% [3] Pharmaceutical Sector - The pharmaceutical sector saw a significant surge, with multiple stocks hitting the daily limit up, including Weikang Pharmaceutical and Chengdu Xian Dao, both reaching a 20% increase [4][5] - Notable stocks in the pharmaceutical sector included: - Chengdu Xian Dao: 21.46 CNY, up 20.02% - Weikang Pharmaceutical: 20.71 CNY, up 19.99% - Other stocks like Lifespring Pharmaceutical and Zhejiang Zhenyuan also saw increases of around 10% [5][6] - The Hong Kong pharmaceutical and biotechnology sector also experienced notable gains, with companies like Fudan Zhangjiang and Kanyin Biotech showing significant price increases [6] Robotics Sector - The humanoid robot concept stocks remained active, with Nanjing Julong hitting the daily limit up of 20%, and other companies like Dongshan Precision and Taijing Technology also seeing substantial gains [7][8] - On July 17, the stock of Aowei New Materials achieved a 20% limit up, marking its seventh consecutive trading day of gains, with a closing price of 27.89 CNY [10][11] Policy Impact - The National Healthcare Security Administration recently announced the initiation of the 11th batch of centralized drug procurement, which will include 55 drug varieties, focusing on mature "old drugs" while excluding innovative drugs from the procurement list [6]

创新药概念股维持强势 维康药业20CM涨停 智通财经7月16日电，维康药业20CM涨停，成都先导涨超10%，力生制药、汉商集团涨停，博济医药、 昂利康、塞力医疗、神州细胞、迈威生物、复旦张江等多股涨超5%。消息面上，7月15日，国家医保局 消息，第十一批国家组织药品集中采购工作日前启动。本次集采坚持"集采非新药、新药不集采"的原 则，也就是说临床使用成熟的"老药"才会纳入集采范围，创新药不会被纳入集采。 ...

创新药板块早盘走强，汉商集团（600774）涨停封板，维康药业（300878）、成都先导涨超15%，塞力 医疗（603716）、南新制药、博济医药（300404）跟涨。 暗盘资金正涌入这些股票，点击速看>>> ...

Group 1 - The A-share innovative drug sector continues to show strong performance, with Weikang Pharmaceutical hitting a 20% daily limit increase [1] - Seer Medical also reached its limit, while companies such as Nanjing New Pharmaceutical, Lianhuan Pharmaceutical, Anglikang, and Boji Medical experienced upward trends [1]